Betamethasone — How Dangerous It Is, Side Effects and Withdrawal Syndrome

EFFECTIVE | TOXIC

Names Under Which Betamethasone Is Available

The international nonproprietary name is betamethasone, and its Latin spelling is Betamethasone. Different derivatives are used in medicinal products: betamethasone dipropionate, betamethasone valerate, betamethasone sodium phosphate and betamethasone acetate.

Dosage forms include creams, ointments, lotions, solutions, ophthalmic and otic preparations, tablets and injectable suspensions. Trade names vary by country: Celestone, Celestone Soluspan, Diprospan, Flosteron, Betaspan Depot, Beloderm, Akriderm, Betnovate, Diprolene and Cutivate.

Combination products may contain betamethasone together with clotrimazole, gentamicin, salicylic acid, calcipotriol or other substances: Akriderm GK, Akriderm SK, Triderm, Belosalik, Diprosalic, Candiderm, Daivobet and their equivalents. Simultaneous use of several such products may imperceptibly increase the total glucocorticoid burden. The composition should be checked by the active substance, not merely by the name on the packaging.

Why Betamethasone Is Considered Harmless and Where the Real Risk Begins

Betamethasone rapidly reduces itching, redness, swelling, and allergic and immune-mediated inflammation. It is precisely this pronounced and rapid effect that creates the impression that a hormonal ointment, injection or tablet simply “relieves inflammation” and can be used repeatedly with every exacerbation.

In reality, betamethasone is a potent synthetic glucocorticoid. It suppresses immune responses, alters glucose, protein and bone metabolism, and can suppress the hypothalamic-pituitary-adrenal axis.

Topical application does not guarantee an exclusively local effect. Absorption increases when the product is applied to a large area, damaged or thin skin, beneath a dressing, in skin folds, on the face or genital area, as well as during prolonged use and use in children. The first complications may resemble an ordinary worsening of the disease: increased redness, burning, rash, weakness or the development of an infection.

Side Effects During Short-Term Use

During topical use, burning, itching, dryness, irritation, folliculitis, acneiform eruptions, allergic contact dermatitis and changes in pigmentation may occur within the first hours or days.

Betamethasone suppresses local immune defence. As a result, a bacterial, fungal or viral infection may spread while becoming less noticeable because inflammation is temporarily reduced.

Application near the eyes increases the risk of ophthalmic complications, particularly with repeated or prolonged exposure.

Following systemic administration, possible effects include elevated blood glucose, fluid retention, increased blood pressure, potassium loss, insomnia, agitation, anxiety, mood changes, dyspepsia and exacerbation of ulcerative lesions of the gastrointestinal tract.

Its immunosuppressive effect may worsen an existing infection or reactivate a latent one.

Life-threatening reactions include anaphylaxis, severe hyperglycaemia, acute psychotic reactions, marked electrolyte disturbances and severe infectious complications.

Epidural administration of injectable betamethasone suspensions is not a safe standard procedure. Spinal cord infarction, paralysis, loss of vision, stroke and fatal outcomes have been reported.

Side Effects During Prolonged or Repeated Use

Prolonged topical use may lead to thinning and atrophy of the skin, dilation of superficial blood vessels, striae, easy bruising, hypopigmentation, hypertrichosis, perioral dermatitis, steroid acne and delayed healing.

Atrophic changes and striae may be only partially reversible. Repeated suppression of local inflammation without eliminating the cause of the disease masks infection and promotes recurrence.

With sufficient systemic absorption, and particularly with tablets and injections, possible effects include Cushing syndrome, central redistribution of adipose tissue, muscle weakness, osteoporosis, fractures, hyperglycaemia and steroid-induced diabetes mellitus, arterial hypertension, cataracts, glaucoma, impaired growth in children, reduced resistance to infections and aseptic necrosis of bone tissue.

Suppression of the body’s own cortisol production may persist after treatment has been discontinued. The absence of noticeable early reactions does not mean that the adrenal glands, bone tissue, skin and metabolism are not being affected.

Contraindications and High-Risk Groups

Betamethasone is contraindicated in patients with hypersensitivity to the active substance or to any component of the specific medicinal product.

Topical forms should not be applied without medical supervision to untreated bacterial, fungal or viral skin lesions, because suppression of the immune response may accelerate the spread of infection.

Prolonged use on the face, eyelids, groin and axillary folds, beneath occlusive dressings, over extensive areas or on damaged skin is particularly risky.

Systemic use requires special assessment in patients with diabetes mellitus, uncontrolled hypertension, peptic ulcer disease, osteoporosis, glaucoma, severe psychiatric disorders, active infections or immunodeficiency states.

Children have a higher ratio of skin surface area to body weight. Consequently, systemic absorption of a topical steroid and adrenal suppression may develop more readily.

In older patients, the consequences of bone and muscle loss may be particularly pronounced.

Latent strongyloidiasis should be considered in patients who have lived in or visited tropical regions. Glucocorticoid-induced immunosuppression may cause Strongyloides hyperinfection, resulting in severe enterocolitis, sepsis and death.

Reactivation of latent amoebiasis and other infections is also possible.

Dangerous Interactions

Combining systemic betamethasone with other glucocorticoids without calculating the total dose is highly undesirable. Hidden duplication may occur when injections, tablets, ointments, nasal, ophthalmic and combination products are used simultaneously. The greater the total exposure, the higher the risk of hyperglycaemia, infections, osteoporosis, Cushing syndrome and adrenal suppression.

Nonsteroidal anti-inflammatory drugs and alcohol increase damage to the gastric mucosa and the likelihood of ulcer-related complications. Potassium-depleting diuretics and certain laxatives increase the risk of hypokalaemia. Under these conditions, the toxicity of cardiac glycosides rises. Betamethasone can increase blood glucose and reduce the effectiveness of glucose-lowering therapy. Concomitant use with immunosuppressants increases susceptibility to infections.

Inducers of hepatic enzymes, including rifampicin, phenytoin, phenobarbital and carbamazepine, may reduce the concentration and effectiveness of the corticosteroid. CYP3A4 inhibitors may, by contrast, increase systemic exposure and the risk of glucocorticoid-related complications. Live vaccines are contraindicated during treatment with immunosuppressive doses or must be postponed. The response to other vaccines may be weakened. Herbal preparations that lower glucose, blood pressure or potassium also require consideration, because they may alter the severity of the metabolic effects of treatment.

Patient Errors

Typical errors include using a potent ointment independently for any type of itching, applying a thicker layer in an attempt to accelerate the effect, treating the face and skin folds, covering the area with plastic film or a tight dressing, continuing treatment for weeks after the symptoms have disappeared and using the medication for an undiagnosed fungal infection.

It is common to mix betamethasone with a cosmetic cream or to apply a combination product “for everything at once,” although the presence of an antibiotic and an antifungal component does not make hormonal treatment safer.

With systemic forms, repeated injections during every exacerbation, independently shortening the intervals, combining several hormonal medicines, ignoring increases in blood glucose and blood pressure and abruptly stopping treatment after a prolonged course are dangerous.

The absence of an immediate complication after a previous injection does not confirm the safety of the next one. Adrenal suppression, bone loss and metabolic disturbances may accumulate without obvious early symptoms.

Overdose and Poisoning

There is no single universal “toxic dose” of betamethasone, because the risk is determined by the dosage form, route of administration, duration of use, area of application, age, coexisting diseases and simultaneous use of other glucocorticoids.

A single ingestion of a small amount of a topical product usually does not cause severe poisoning. However, massive systemic administration, repeated injections, mistakenly shortened intervals or prolonged excessive use may cause pronounced hypercortisolism.

During the first hours and days, agitation, insomnia, increased blood pressure and blood glucose, fluid retention, dyspepsia and electrolyte disturbances may occur. With continued exposure, muscle weakness, oedema, infections, psychiatric disturbances, hypokalaemia and decompensation of diabetes may develop.

Chronic overdose presents with Cushing syndrome, skin atrophy, striae, osteoporosis, muscle atrophy and suppression of the hypothalamic-pituitary-adrenal axis.

There is no specific antidote. Treatment is based on stopping excessive exposure, correcting electrolyte and glucose disturbances, controlling blood pressure, treating infectious complications and assessing adrenal function.

After prolonged or substantial systemic exposure, the medication must not be stopped mechanically. Abrupt discontinuation may cause acute adrenal insufficiency with severe weakness, a fall in blood pressure, nausea, vomiting, abdominal pain, impaired consciousness and vascular collapse.

A Safe Integrative Alternative to Betamethasone

An integrative alternative to betamethasone should be selected according to the purpose for which the glucocorticoid was prescribed.

For moderate chronic inflammation of the joints, tendons and soft tissues, an oral combination of dry extracts of Boswellia serrata and Curcuma longa may be used. Boswellic acids predominantly inhibit the 5-lipoxygenase and leukotriene components of inflammation, while curcuminoids affect NF-κB, cyclooxygenase pathways and the production of pro-inflammatory cytokines.

The combination does not reproduce the total immunosuppressive action of betamethasone, but it may reduce pain, stiffness and the severity of chronic inflammation without the adrenal suppression, osteoporosis, steroid-induced diabetes and Cushing syndrome characteristic of systemic glucocorticoids.

The most convincing clinical evidence has been obtained in osteoarthritis and chronic musculoskeletal disorders. In a severe systemic autoimmune process, this combination is not an equivalent substitute for a glucocorticoid.

Boswellia serrata and Curcuma longa are taken orally as dry extracts. Dosing should be determined by the actual standardisation of the specific raw material, not merely by the weight of the powder.

Boswellia may cause dyspepsia and individual allergic reactions. Turmeric requires caution in gallstone disease, impaired bile flow, a tendency to bleed and concomitant use of anticoagulants or antiplatelet agents. Herbal extracts should also not be mechanically added to complex treatment without assessing interactions.

For local non-infectious dermatitis, eczematous inflammation, dryness and itching, a topical ointment made from dry extracts of Nigella sativa and Scutellaria baicalensis may be used.

Nigella sativa is the main anti-inflammatory component. In a clinical study of hand eczema, a topical product containing Nigella sativa reduced the severity of symptoms and was compared with betamethasone. However, this does not mean that any homemade formulation can be regarded as pharmaceutically equivalent to a registered corticosteroid.

Scutellaria baicalensis complements the formulation with flavonoids, including baicalin and baicalein, but the clinical evidence for topical use of this combination remains limited.

Ointment Made from Nigella sativa and Scutellaria baicalensis Extracts

To prepare 100 g of ointment, use 5 g of dry Nigella sativa extract, 5 g of dry Scutellaria baicalensis extract, 70 g of coconut oil, 15 g of beeswax and 5 g of lanolin.

Heat the coconut oil and beeswax in a water bath to approximately 55–60 °C until completely melted. Add the lanolin and mix.

Triturate each dry extract separately with a small amount of the warm base until a smooth paste without dry lumps is obtained. Gradually incorporate the pastes into the main mixture with constant stirring.

After the extracts have been evenly distributed, cool the ointment to approximately 40 °C and place it into clean, dry jars made of dark glass.

This preparation is an individual extemporaneous formulation, not a registered medicinal product with confirmed stability and standardised release.

Dry extracts may not dissolve completely in the fatty base. Therefore, before use, the uniformity, odour, colour changes and signs of separation should be assessed.

Some published formulations of Nigella sativa and Scutellaria ointments also use coconut oil, wax and a 5% topical concentration of Scutellaria extract.

Apply a thin layer of the ointment to a small area of non-infected skin once or twice daily. Before the first full application, perform a test on an area of approximately 1 cm² and observe the reaction for at least 24 hours.

If burning, itching, swelling, oozing or redness increases, wash the product off and do not use it again. Nigella sativa itself may cause allergic contact dermatitis.

Do not apply the ointment to the eyelids, mucous membranes, open wounds, deep fissures, ulcers, purulent lesions, active herpes, extensive oozing surfaces or areas where a fungal infection is suspected.

It should not be used to mask a rash of unknown origin. In cases of widespread dermatitis, fever, pain, blisters, necrosis, purulent discharge or rapid enlargement of the lesion, diagnosis is required rather than continued application of an anti-inflammatory ointment.

Store the ointment in a tightly closed jar in a cool, dark place and prevent water from entering it.

For a homemade formulation without microbiological control, it is reasonable to prepare a small amount and use it within 30 days.

The appearance of an unusual odour, mould, gas, separation or a marked colour change is grounds for disposal.

Neither the oral combination of Boswellia serrata and Curcuma longa nor the topical ointment made from Nigella sativa and Scutellaria baicalensis prevents adrenal insufficiency caused by prolonged systemic use of betamethasone. Abrupt withdrawal of a glucocorticoid after suppression of the hypothalamic-pituitary-adrenal axis may cause acute adrenal insufficiency and an adrenal crisis. Therefore, herbal products cannot be used instead of gradual dose reduction and medical monitoring of the recovery of cortisol secretion.

Betamethasone remains necessary in severe allergic reactions, pronounced airway oedema, severe exacerbations of bronchial asthma, active systemic autoimmune inflammation, severe dermatoses and other conditions requiring rapid, potent and predictable suppression of inflammation. In such situations, herbal preparations may be considered only after the condition has stabilised and must not delay standard emergency treatment.

Actual Effectiveness of Betamethasone

Betamethasone is genuinely effective as a potent glucocorticoid. It rapidly suppresses inflammatory, allergic and immune responses and reduces oedema, itching, redness, exudation and pain associated with inflammation.

Topical forms are effective in corticosteroid-responsive dermatoses, including certain forms of eczema, dermatitis and psoriasis. Systemic and injectable forms may be used in severe allergic, rheumatological, inflammatory and other conditions requiring a pronounced glucocorticoid effect.

The medication suppresses the inflammatory process but often does not eliminate its underlying cause. In contact dermatitis, it does not eliminate contact with the allergen. In a fungal infection, it does not destroy the causative organism. In osteoarthritis, it does not restore damaged cartilage. In a chronic autoimmune disease, it does not guarantee lasting remission after withdrawal.

Rapid disappearance of visible symptoms may mask the persisting disease and create the illusion that its cause has been treated.

Medical errors include prescribing a potent topical form without clarifying the diagnosis, using it for fungal or viral skin lesions, prolonged courses on the face and in skin folds, failure to calculate the total area of application, repeated injections without assessing the accumulated glucocorticoid burden and ignoring diabetes mellitus, osteoporosis, infections and the risk of adrenal suppression.

The medication works effectively, but the physiological cost of its effect increases with the dose, duration of treatment and area of exposure.

Safety Monitoring During Treatment

During short-term topical use on a limited area, the condition of the skin should be monitored. Increased redness, the appearance of oozing, pustules, vesicles, tenderness, a white coating, clearly defined ring-shaped borders or spread of the lesion may indicate an infection or a contact reaction.

With prolonged use, the skin should be assessed for thinning, the appearance of visible superficial blood vessels, striae, bruising, changes in pigmentation and impaired healing.

When potent forms are applied to a large surface area, beneath a dressing or to damaged skin, or when a child is being treated, assessment of the hypothalamic-pituitary-adrenal axis may be required.

Morning cortisol is measured and, if necessary, a stimulation test with adrenocorticotropic hormone is performed. A normal outward appearance does not exclude suppression of cortisol secretion.

During systemic use, blood pressure, body weight, oedema, blood glucose, potassium, signs of infection, psychiatric reactions and the condition of the gastrointestinal tract are monitored.

During prolonged courses, bone density, eye health, muscle strength and the risk of osteoporotic fractures are additionally assessed.

Difficulty breathing, swelling of the face or larynx, pronounced weakness accompanied by a fall in blood pressure, impaired consciousness, severe hyperglycaemia, black stools, vomiting blood, sudden visual impairment, a severe psychotic reaction, high fever during immunosuppression and a rapidly spreading infectious skin lesion require immediate medical assessment.

With such symptoms, continuing self-treatment may lead to vascular collapse, sepsis, gastrointestinal bleeding or irreversible loss of vision.

Proper Withdrawal of Betamethasone and the Consequences of Discontinuing Treatment

A short topical course on a small area can usually be discontinued without a special gradual reduction in dose.

However, after prolonged application of potent betamethasone, particularly on the face, skin folds, extensive areas or beneath an occlusive dressing, rebound inflammation, pronounced redness, burning, oedema, itching and rapid recurrence of the dermatosis may occur.

In such cases, the frequency of application is gradually reduced or the patient is switched to a less potent topical product under specialist supervision.

Systemic betamethasone must not be stopped abruptly after a prolonged course or repeated high doses.

An exogenous glucocorticoid reduces the secretion of corticotropin-releasing hormone and adrenocorticotropic hormone. As a result, the adrenal glands temporarily reduce their production of endogenous cortisol. Recovery may take weeks or months.

Stopping treatment too quickly may cause weakness, malaise, muscle and joint pain, loss of appetite, nausea, vomiting, abdominal pain, a fall in blood pressure, hypoglycaemia and impaired consciousness.

The severe form presents as an adrenal crisis.

At the same time, the disease that was being suppressed by the medication may return. It is therefore necessary to distinguish withdrawal syndrome, adrenal insufficiency and recurrence of the underlying inflammatory process.

The dose reduction schedule depends on the initial dose, duration of treatment, route of administration, frequency of repeated courses and the patient’s condition.

There is no single universal tapering schedule for all forms of betamethasone.

The closer the dose is to the physiological glucocorticoid level, the more slowly further reduction is usually carried out.

If there is uncertainty, recovery of adrenal function is confirmed by measuring morning cortisol or by a stimulation test.

Oral extracts of Boswellia serrata and Curcuma longa and a topical ointment made from Nigella sativa and Scutellaria baicalensis may be added only as means of controlling the corresponding inflammatory symptoms.

They do not replace a glucocorticoid during recovery of adrenal function and do not protect against an adrenal crisis.

A Rational Approach to Treatment

Betamethasone is justified when rapid and powerful suppression of inflammation, an allergic reaction or pathological immune activity is required. In severe and unstable conditions, its action may be clinically necessary, and attempting to replace it with a slowly acting herbal product may worsen the prognosis.

The problem begins when a potent glucocorticoid becomes a routine remedy for any rash, pain or inflammation. Repeated injections, prolonged application to the skin and independently extending the course increase the risk of skin atrophy, infection, hyperglycaemia, osteoporosis, Cushing syndrome and adrenal suppression.

In moderate chronic inflammation of the musculoskeletal system, an oral combination of Boswellia serrata and Curcuma longa may reduce the need for repeated systemic use of a glucocorticoid. In limited non-infectious inflammation of the skin, a topical ointment made from Nigella sativa and Scutellaria baicalensis may be used as a gentler option if the diagnosis has been established and infectious lesions have been excluded.

The aim of an integrative approach is not the mechanical rejection of effective betamethasone, but its use only where the strength and speed of action are genuinely necessary. In all other cases, the total glucocorticoid burden should be reduced, the cause of inflammation should be addressed, unjustified repeated courses should be avoided and less toxic agents should be used when they can achieve a comparable therapeutic objective.

If you have any questions about the subject of this article, you can ask a clinical pharmacologist in the comments or make an appointment using the following link https://asiabiopharm.com/konsultaciii/